BZR2 Antibody

What is BZR2 and why are antibodies against it important in plant science?

BZR2 (also known as BES1) belongs to the Brassinozale-Resistant (BZR) family of transcription factors that mediate brassinosteroid (BR) signaling responses. Similar to its homolog BZR1, BZR2 is regulated through phosphorylation by GSK3-like kinases such as Brassinosteroid-Insensitive 2 (BIN2) . When BR levels are low, BZR2 becomes phosphorylated, which inhibits its DNA-binding activity and causes cytoplasmic retention. Conversely, in the presence of BR, BZR2 is activated through dephosphorylation, allowing it to regulate BR-responsive gene expression.

Antibodies against BZR2 are crucial for:

• Monitoring BZR2 protein levels in different plant tissues

• Assessing phosphorylation status in response to BR

• Studying protein-protein interactions in BR signaling

• Investigating DNA-binding activities through ChIP assays

• Examining subcellular localization during signaling events

How can I verify the specificity of a BZR2 antibody?

Verifying antibody specificity is critical for reliable results. For BZR2 antibodies, implement these methodological approaches:

• Western blot validation:

  • Compare wild-type plants with bzr2 mutants or knockdown lines

  • Include both phosphorylated and dephosphorylated forms of BZR2

  • Test for cross-reactivity with BZR1 (high sequence similarity in some regions)

• Immunoprecipitation followed by mass spectrometry:

  • Perform IP-MS to identify all proteins captured by the antibody

  • Confirm BZR2 as the predominant captured protein

• Preabsorption controls:

  • Incubate the antibody with purified recombinant BZR2 protein

  • Compare immunostaining patterns with and without preabsorption

• Flow cytometry:

  • Similar to techniques used for ErbB2/Her2 antibody validation , test binding specificity using cells overexpressing BZR2

What are the optimal conditions for Western blotting with BZR2 antibodies?

Optimizing Western blotting for BZR2 requires special attention to preserve phosphorylation status and prevent degradation:

Sample preparation protocol:

• Extract proteins in buffer containing phosphatase inhibitors (10 mM NaF, 1 mM Na3VO4)

• Include protease inhibitors to prevent degradation

• For phosphorylation studies, use Phos-tag™ gels to separate phosphorylated from unphosphorylated forms

Western blotting conditions:

• Transfer: Use wet transfer at low voltage (30V) overnight at 4°C

• Blocking: 5% BSA in TBST (preferred over milk for phospho-epitopes)

• Primary antibody: Incubate at 1:1000 dilution overnight at 4°C

• Visualization: Use chemiluminescence or fluorescent secondary antibodies

Troubleshooting tip: If detecting multiple bands, determine if they represent different phosphorylation states by treating samples with lambda phosphatase prior to electrophoresis.

How do I optimize immunohistochemistry protocols for plant tissues using BZR2 antibodies?

Plant tissues require specialized processing for effective BZR2 immunohistochemistry:

• Fixation and embedding:

  • Fix tissues in 4% paraformaldehyde for 4-6 hours

  • For paraffin embedding, use a graded ethanol series followed by xylene substitution

  • For cryosectioning, infiltrate with 30% sucrose before OCT embedding

• Antigen retrieval methods:

  • Heat-induced epitope retrieval: 10 mM sodium citrate buffer (pH 6.0) at 95°C for 20 minutes

  • Enzymatic retrieval: 0.01% trypsin at 37°C for 10 minutes

• Primary antibody application:

  • Optimal dilution: 1:100 to 1:200 (must be empirically determined)

  • Incubation: Overnight at 4°C in humidity chamber

  • Include negative controls (no primary antibody and pre-immune serum)

• Signal detection optimization:

  • Use tyramide signal amplification for weak signals

  • Counterstain nuclei with DAPI to visualize subcellular localization

How can I use proximity labeling techniques to study BZR2 protein interactions?

Proximity labeling offers significant advantages for studying transient BZR2 interactions in intact plant cells:

TurboID-mediated proximity labeling protocol:

• Generate transgenic plants expressing BZR2-TurboID fusion protein

• For transient expression, use Agrobacterium-mediated transformation of Nicotiana benthamiana leaves

• Feed biotin (50 μM) for 1-4 hours during active BR signaling

• Extract proteins under denaturing conditions (1% SDS buffer)

• Capture biotinylated proteins using streptavidin beads

• Analyze by mass spectrometry to identify proximity partners

This approach has demonstrated superior sensitivity compared to traditional co-immunoprecipitation for detecting BZR1 interactions , with approximately 10-fold higher efficiency. Based on BZR1 studies, proximity labeling will likely capture both the phosphorylation machinery (BIN2, PP2A) and DNA-binding partners of BZR2.

Data analysis considerations:

• Use appropriate controls (TurboID-only expression)

• Filter out common contaminants from mass spectrometry data

• Validate key interactions using traditional methods (Y2H, BiFC)

What are the best approaches for using BZR2 antibodies in ChIP-seq experiments?

ChIP-seq with BZR2 antibodies requires careful optimization to identify genomic binding sites:

Optimized ChIP-seq protocol for plant transcription factors:

• Crosslinking and chromatin preparation:

  • Crosslink with 1% formaldehyde for 10 minutes

  • Quench with 0.125 M glycine

  • Sonicate to generate 200-300 bp fragments

  • Verify fragmentation efficiency by gel electrophoresis

• Immunoprecipitation optimization:

  • Pre-clear chromatin with protein A/G beads

  • Use 2-5 μg antibody per sample

  • Include controls: IgG negative control and input samples

  • Wash stringently to reduce background (use LiCl wash buffer)

• Library preparation considerations:

  • Use as little as 1-10 ng DNA for library preparation

  • Include spike-in controls for normalization

  • Sequence to minimum depth of 20 million reads

• Data analysis pipeline:

  • Align reads to reference genome

  • Call peaks using MACS2 or similar algorithms

  • Perform motif enrichment analysis

  • Compare binding profiles in different hormone treatments

In studies with BZR1, ChIP-qPCR showed enhanced binding to target promoters (PRE1, PRE5, IAA19, SAUR-AC1, and DWF4) following GA treatment . Similar experiments with BZR2 can reveal how hormone crosstalk affects its genomic occupancy.

How can I distinguish between phosphorylated and non-phosphorylated forms of BZR2 using antibodies?

Distinguishing phosphorylation states of BZR2 is crucial for understanding its activation status:

Method 1: Phospho-specific antibodies

• Use antibodies specifically raised against phosphorylated BZR2 peptides

• Validate specificity with lambda phosphatase-treated controls

• Develop separate antibodies for different phosphorylation sites

Method 2: Mobility shift assays

• Based on studies with BZR1, the phosphorylated form migrates more slowly on SDS-PAGE

• Use 8% SDS-PAGE gels to maximize separation

• Include BR-treated and untreated samples as controls

Method 3: Phos-tag™ SDS-PAGE

• Incorporate Phos-tag™ reagent in polyacrylamide gels

• This significantly enhances separation of phosphorylated proteins

• Protocol: Add 50 μM Phos-tag™ and 100 μM MnCl₂ to standard gel recipe

Quantitative analysis:

• Use densitometry to quantify the ratio of phosphorylated to non-phosphorylated forms

• Present results as a table showing changes across different treatments:

How can I design and validate bispecific antibodies for studying BZR2 interactions with other proteins?

Bispecific antibodies that simultaneously recognize BZR2 and interacting partners can provide powerful tools for studying protein complexes:

Design considerations:

• Target epitope selection:

  • Choose epitopes that don't interfere with protein-protein interactions

  • For BZR2, avoid the DNA-binding domain and regions involved in known interactions

  • Select epitopes with high accessibility

• Bispecific antibody format:

  • Consider dual-variable domain (DVD) format for full IgG-based recognition

  • Use smaller formats (BiTE, DART) for better tissue penetration

  • Balance molecular weight against stability and half-life

• Expression system:

  • Use mammalian expression (Expi293 cells) for proper folding and glycosylation

  • Purify using sequential affinity steps to ensure dual specificity

Validation protocol:

• Binding specificity:

  • Perform ELISAs against individual proteins and mixtures

  • Use surface plasmon resonance to measure binding kinetics to each target

  • Compare affinities to parent monospecific antibodies

• Functional validation:

  • Test ability to co-immunoprecipitate protein complexes

  • Perform proximity ligation assays in fixed cells/tissues

  • Use in ChIP experiments to detect co-binding proteins

Bispecific antibodies targeting BZR2 and RGA (based on the BZR1-RGA interaction model ) could provide insights into BR-GA signaling crosstalk.

How do I design co-immunoprecipitation experiments to study BZR2 protein interactions?

Co-immunoprecipitation experiments require careful optimization for studying BZR2 complexes:

Recommended Co-IP protocol:

• Buffer optimization:

  • Use mild lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40)

  • Include protease and phosphatase inhibitors

  • For phospho-dependent interactions, maintain phosphorylation status with 50 mM NaF

• Pre-clearing strategy:

  • Pre-clear lysates with protein A/G beads for 1 hour at 4°C

  • Remove non-specific binding proteins with species-matched IgG

• Antibody coupling:

  • Directly couple antibodies to beads to avoid IgG contamination

  • Use 2-5 μg antibody per mg of total protein

  • For reproducibility, prepare crosslinked antibody-bead conjugates

• Controls and validation:

  • Include IgG negative controls

  • Use competing peptides as specificity controls

  • Validate key interactions with reciprocal IP

Based on findings with BZR1, note that interactions may be phosphorylation-dependent. For example, RGA only binds unphosphorylated BZR1 , suggesting phosphorylation state may regulate BZR2 interactions as well.

What are the best methods for quantifying BZR2 protein abundance in different plant tissues?

Accurate quantification of BZR2 is essential for understanding its regulation:

Method 1: Western blot quantification

• Use recombinant BZR2 protein standards for absolute quantification

• Include loading controls (actin, tubulin, or total protein stain)

• Analyze with densitometry software (ImageJ) using standard curves

Method 2: ELISA-based quantification

• Develop sandwich ELISA using two non-competing BZR2 antibodies

• Establish standard curves with recombinant protein

• Implement for high-throughput analysis of multiple samples

Method 3: Mass spectrometry with isotope labeling

• Use stable isotope-labeled peptide standards

• Target unique BZR2 peptides for selected reaction monitoring

• Provides absolute quantification with high specificity

Sample preparation considerations:

• For developmental studies, use consistent tissue amounts and extraction methods

• For hormone treatments, establish clear time courses and concentrations

• For subcellular fractionation, verify fraction purity with marker proteins

How can I use BZR2 antibodies to investigate crosstalk between brassinosteroid and other hormone signaling pathways?

Investigating signaling crosstalk requires specialized experimental approaches:

Experimental approaches:

• Double immunoprecipitation method:

  • First IP: Pull down BZR2 complexes with anti-BZR2 antibody

  • Second IP: Use antibodies against components of other signaling pathways

  • Identify mutual interacting partners through this sequential process

• Hormone time-course experiments:

  • Treat plants with BR alone or in combination with other hormones (GA, auxin, ABA)

  • Immunoprecipitate BZR2 at different time points

  • Identify differential interactors by mass spectrometry

• ChIP-reChIP technique:

  • First ChIP: BZR2 antibody

  • Second ChIP: Antibodies against other transcription factors

  • Identifies genomic regions jointly regulated by multiple factors

Based on BZR1 studies , focus on the interactions with DELLA proteins (RGA/GAI) as a model for BR-GA crosstalk. The data indicates that GA enhances BZR1 binding to target promoters by reducing DELLA protein levels, which otherwise block DNA binding. Similar mechanisms likely exist for BZR2.

How can computational approaches complement experimental studies using BZR2 antibodies?

Computational methods are increasingly important for antibody-based BZR2 research:

Integrative computational approaches:

• Antibody structure prediction and optimization:

  • Use approaches like AbMAP for modeling antibody-antigen interactions

  • Predict binding epitopes based on BZR2 structure

  • Design antibodies with customized specificity profiles

• Network analysis of protein interactions:

  • Integrate antibody-derived interaction data into protein-protein interaction networks

  • Use graph theory to identify hub proteins and signaling modules

  • Predict novel interactions based on network topology

• AI-assisted experimental design:

  • Use machine learning to optimize antibody-based experimental conditions

  • Implement automated analysis pipelines for image-based data

  • Develop predictive models for antibody specificity and cross-reactivity

Computational approaches have demonstrated high predictive power, with one study showing an 82% success rate in predicting both strong and weak binders .

How can I develop a BZR2 antibody with reduced cross-reactivity to BZR1?

Developing highly specific antibodies against closely related proteins requires specialized approaches:

Target selection strategy:

• Perform sequence alignment between BZR2 and BZR1

• Identify regions with lowest sequence identity

• Prioritize epitopes in variable regions, especially outside functional domains

• Avoid conserved DNA-binding domains and phosphorylation sites

Negative selection approach:

• Implement alternating rounds of positive selection against BZR2 and negative selection against BZR1

• Use phage display technology with appropriate screening methods

• Apply biophysics-informed computational modeling to predict cross-reactivity

Validation experiments:

• Test against recombinant BZR1 and BZR2 proteins

• Use transgenic plants with modified BZR1/BZR2 expression

• Perform epitope mapping to confirm binding specificity

A recent study demonstrated successful development of highly specific antibodies using biophysics-informed models, achieving customized specificity profiles for closely related epitopes .

What are emerging technologies for studying BZR2 using antibody-based approaches?

Several cutting-edge technologies are expanding the capabilities of antibody-based research:

Single-cell protein analysis:

• Mass cytometry (CyTOF) with metal-conjugated antibodies

• Single-cell Western blotting for heterogeneity studies

• Microfluidic antibody capture for rare cell analysis

Super-resolution microscopy techniques:

• STORM and PALM imaging with specialized antibody labeling

• Expansion microscopy for enhanced spatial resolution

• Live-cell single-molecule tracking with Fab fragments

Antibody engineering innovations:

• Small format antibodies (nanobodies, affibodies) for improved tissue penetration

• Split antibody complementation for studying protein interactions

• Photoswitchable antibodies for optogenetic applications

Recommended implementation strategy:

• Begin with well-validated conventional methods

• Establish controls and benchmarks for comparison

• Implement new technologies to address specific limitations or questions

This systematic approach ensures continuity of research while incorporating technological advancements.

What are the critical quality control steps for ensuring reliable results with BZR2 antibodies?

Rigorous quality control is essential for generating reproducible data:

Antibody validation checklist:

• Genetic validation: Test in knockout/knockdown plants

• Biochemical validation: Western blot with recombinant protein

• Immunoprecipitation validation: Mass spectrometry confirmation

• Application-specific validation: Test in each experimental system

Experiment-specific controls:

• Positive controls: Samples with known BZR2 expression

• Negative controls: Samples lacking BZR2 expression

• Technical controls: Secondary antibody-only, isotype controls

• Treatment controls: BR-treated vs. untreated samples

Documentation requirements:

• Antibody catalog number, lot number, and dilution

• Validation data and optimization parameters

• Complete experimental conditions and protocols

• Raw data preservation for reanalysis

Following these best practices ensures research reliability and facilitates troubleshooting when unexpected results occur.